In the CheckMate 017 and 057 trials, nivolumab prolonged overall survival (OS) compared with docetaxel in patients with previously treated non‐small cell lung cancer (NSCLC).2, 3 In the KEYNOTE 024 trial, pembrolizumab was significantly associated with longer OS than platinum‐doublet chemotherapy in patients with previously untreated advanced NSCLC with strongly positive tumor PD‐L1 expression.4 Atezolizumab is a monoclonal antibody that targets PD‐L1. Here, CD274 is linked to lung cancer.